Remove Allergies Remove Bacterium Remove Clinical Trials Remove Trials
article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

article thumbnail

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). This trial will evaluate the safety of the vaccine and generate efficacy data. Intravacc has received a contract worth $14.6m

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Probiotics increase gut bacteria diversity in extremely preterm infants

Scienmag

A new clinical study has shown that supplements of a lactic acid bacterium may have positive effects by increasing the diversity of intestinal bacteria in these infants. Extremely preterm infants can suffer from a life-threatening inflammation of the gut.

article thumbnail

New Research Shows IBS Symptoms May be Caused by Gut Infections

XTalks

However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease. Moreover, the response did not induce symptoms typical of a food allergy. This is further proof that the mechanism we have unraveled has clinical relevance,” said Professor Boeckxstaens.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. There was a record 34 approvals in major markets, and late-stage trials are commencing for medications including camizestrant, datopotamab deruxtecan and volrustomig.

Sales 98
article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

As of November, the WHO has discouraged the use of the drug as the agency’s review of data from four different clinical trials yielded no worthy effect on mortality, need for mechanical ventilation, time to clinical improvement or any other important patient outcomes. Vaccine Considerations. CRISPR Therapeutics.